Skip to main content

Table 3 Effect of Doxorubicin (DOX) and different treatments of AHE on hepatic phase II antioxidant enzymes and GSH profile

From: Effect of Acacia hydaspica R. Parker extract on lipid peroxidation, antioxidant status, liver function test and histopathology in doxorubicin treated rats

Treatment (mg/kg) GSH (μM/g tissue) GR (nM/min/mg protein) GST (nM/min/mg protein) γ-GT (nM/min/mg Protein) GPx (nM/min/mg Protein)
Control 19.61 ± 0.283b 163.6 ± 0.656b 142.6 ± 0.57b 336.2 ± 0.564b 139.5 ± 1.164b
DOX 10.46 ± 0.660a 101.4 ± 0.599a 99.72 ± 1.08a 141.6 ± 0.296a 92.58 ± 0.752a
AHE alone 20.11 ± 0.158b 164.2 ± 0.677b 142.7 ± 0.89b 336.3 ± 0.999b 139.8 ± 0.355b
DOX + AHE (200) 12.50 ± 0.397a, d 134.8 ± 0.81a, b, d 118.7 ± 1.81a, b, d* 199.2 ± 1.610a, b, d 111.3 ± 0.874a, b, d
DOX + AHE (400) 17.43 ± 0.599a*, b, c 149.8 ± 0.91a, b, c 130.8 ± 1.86a**, b, c** 306.8 ± 0.779a, b, c 130.5 ± 1.192a, b, c
DOX + Sily 17.32 ± 0.387a*, b 152.7 ± 1.671a, b 128.3 ± 2.82a, b 307.9 ± 1.246a, b 130.9 ± 0.344a, b
  1. Values expressed as mean ± SEM. a Significance at p < 0.0001 Vs. control group, b Significance at p < 0.0001 Vs. Doxorubicin (DOX) group, c Significance at p < 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d Significance at p < 0.0001 of AHE co-treatment groups Vs DOX + Sily group. *, ** Significant difference at p < 0.05 and p < 0.001 respectively. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin